Leadership Overview
Alexion has 6 executives leading key functions including human resources, medical operations, revenue management, strategic development, marketing, and corporate leadership.
Committed to transforming lives through rare disease research, Alexion advances global biopharmaceutical innovation by delivering life-saving therapies for patients facing severe, life-threatening disorders.
Committed to transforming lives through rare disease research, Alexion advances global biopharmaceutical innovation by delivering life-saving therapies for patients facing severe, life-threatening disorders.
Leadership Roles at Alexion
Patrice Coissac - President
Patrice Coissac, the President at Alexion, directs the overall corporate strategy and operational execution for the global biopharmaceutical organization. By setting the vision for research and commercial success, the President ensures that all departments remain focused on the mission of treating rare disorders. Coissac oversees the executive team to maintain alignment with the company's long-term growth objectives. This leadership role involves representing the company to investors, partners, and the broader medical community. Through strategic decision-making, the President navigates the complexities of the global pharmaceutical landscape to ensure sustained innovation. Patrice Coissac also fosters a culture of excellence and accountability across all international operations. By prioritizing the development of life-saving medicines, the executive leadership function drives the company's impact on patient health. Ultimately, Coissac secures the strategic direction required to maintain the company's position as a leader in the biopharmaceutical industry.
Annie Mirabelli - Executive Vice President & Chief Human Resources Officer
Annie Mirabelli, the Executive Vice President & Chief Human Resources Officer at Alexion, directs the global talent strategy and organizational culture initiatives. By aligning workforce capabilities with the biopharmaceutical mission, the Executive Vice President & Chief Human Resources Officer fosters an environment conducive to scientific breakthrough and operational excellence. Mirabelli oversees recruitment, leadership development, and employee engagement programs across all international sites. This role ensures the company attracts top-tier scientific talent necessary for developing medicines for rare disorders. Through rigorous performance management systems, the Executive Vice President & Chief Human Resources Officer maintains high standards of productivity and innovation. Annie Mirabelli also collaborates with the board to refine compensation structures that incentivize long-term research goals. By prioritizing diversity and inclusion, the human resources function strengthens the overall capacity to address complex medical challenges. Ultimately, Mirabelli secures the human capital required to sustain the company's competitive edge in the rare disease market.
Sean Gorman - Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Sean Gorman, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer at Alexion, manages the commercialization strategy for rare disease therapies. By integrating medical insights with market data, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer optimizes product positioning across North American and European markets. Gorman leads cross-functional teams to ensure seamless delivery of life-saving medicines to patients. This leadership role involves analyzing market trends to identify growth opportunities within the biopharmaceutical sector. Through strategic planning, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer aligns marketing efforts with clinical development milestones. Sean Gorman also coordinates with the medical office to ensure accurate communication of therapeutic benefits to healthcare providers. By streamlining operational workflows, the marketing function enhances the efficiency of product launches. Ultimately, Gorman drives revenue growth while maintaining a steadfast focus on patient outcomes and therapeutic accessibility.
Yi Su - Chief Revenue Officer & Manager
Yi Su, the Chief Revenue Officer & Manager at Alexion, architects the financial growth strategy and revenue generation models for the company's rare disease portfolio. By overseeing global sales operations, the Chief Revenue Officer & Manager ensures consistent market penetration and financial stability. Su manages complex pricing strategies that reflect the high value of specialized biopharmaceutical treatments. This leadership role involves close collaboration with the finance department to forecast revenue streams and optimize resource allocation. Through data-driven decision-making, the Chief Revenue Officer & Manager identifies emerging market opportunities and mitigates commercial risks. Yi Su also directs the implementation of sales force effectiveness programs to maximize reach among specialized medical practitioners. By fostering strong relationships with key stakeholders, the revenue function supports the long-term sustainability of the company's research pipeline. Ultimately, Su secures the financial foundation necessary for continued investment in life-threatening disorder treatments.
Mackenzie Halter - Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development
Mackenzie Halter, the Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development at Alexion, coordinates the strategic alignment between regulatory compliance and clinical development. By managing the operational interface for safety protocols, the Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development ensures that all research activities meet rigorous global standards. Halter facilitates communication between the development teams and regulatory bodies to expedite the approval process for new therapies. This leadership role involves overseeing project timelines and resource distribution to maintain development momentum. Through strategic planning, the Operations Senior Director, Strategy & Chief of Staff To, Regulatory & Safety Head of Development optimizes the path from discovery to commercialization. Mackenzie Halter also supports the head of development in executing long-term research objectives. By streamlining internal processes, the strategy function enhances the efficiency of the entire development lifecycle.
Moh-Lim Ong - Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer
Moh-Lim Ong, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer at Alexion, focuses on the operational execution of medical affairs and patient-centric marketing initiatives. By driving the integration of medical data into commercial strategies, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer ensures that therapeutic value is clearly communicated to the medical community. Ong oversees the planning of medical education programs that support the adoption of rare disease treatments. This leadership role involves managing the operational infrastructure that supports the medical office's interactions with healthcare systems. Through strategic oversight, the Director, Business Planning & Operations Medical Office Chief & Chief Marketing Officer aligns marketing campaigns with clinical evidence. Moh-Lim Ong also collaborates with regional teams to adapt commercial strategies to local market needs. By optimizing operational processes, the medical marketing function enhances the company's ability to reach underserved patient populations.
Explore Leadership Teams in Manufacturing
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, United Kingdom. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth-largest pharmaceutical company globally. The company discovers, develops, manufactures, and delivers medicines and vaccines with a research and development focus on four primary therapeutic areas: respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. GSK's product portfolio includes specialty medicines, vaccines, and general medicines targeting conditions such as HIV, respiratory diseases, cancer, immuno-inflammation, anti-viral, central nervous system disorders, metabolic conditions, cardiovascular disease, urogenital conditions, anti-bacterial treatments, dermatology, and rare diseases. The company also offers over-the-counter products for pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. In July 2024, the company moved its global headquarters to New Oxford Street in central London, positioning itself within the city's Knowledge Quarter near world-class science and academic institutions including the Francis Crick Institute and King's College London. The new headquarters houses approximately 3,000 employees including the global leadership team and teams supporting research and development, supply chain, commercial operations, and corporate functions. GSK sells its products through wholesalers, pharmacies, hospitals, physicians, and other healthcare groups globally, aiming to positively impact the health of 2.5 billion people by the end of the decade.
Company Leadership SN
SV
Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company is headquartered in Tokyo, Japan
Company Leadership KS
AP
AM
SS
Sarepta Therapeutics, Inc. is a global commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company is focused on the discovery, development, and commercialization of precision genetic medicines for rare diseases, with particular leadership in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. Sarepta's multi-platform Precision Genetic Medicine Engine spans gene therapy, RNA-targeted therapeutics, and gene editing modalities. The company holds multiple FDA-approved treatments and maintains a broad pipeline of programs across neuromuscular and central nervous system disorders. Sarepta operates globally with locations across North America, Europe, and Asia, and trades on the NASDAQ under the ticker symbol SRPT.
Company Leadership
AN
ZG
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Company Leadership
RF
SK
CW
Frequently Asked Questions Regarding Alexion Top Executives and Leadership Team
